TICKERNERD
Menu
CYTKCYTKHealthcare · Biotechnology

CYTK Stock Forecast: Cytokinetics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$76
−0.88% on the day

The 22 Wall Street analysts covering Cytokinetics, Inc. hold a median 12-month price target of $105 — +37.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 1 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$10.4B
Ticker Nerd rank
74 / 100
Median analyst target
$105
Analysts covering
22
Total return, dividends reinvested
1W
−5.2%
1M
−11.6%
YTD
+20.3%
1Y
+108.4%
From 52W high
−12.4%
From 52W low
+130.1%
$33
$87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CYTK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cytokinetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
93
Revisions
84
Volatility
79
Value
77
Accruals
69
Growth
60
Quality
54
Size
16
Issuance
10

Momentum (93): The shares have been drifting up relative to others.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Cytokinetics, Inc. — and when they’d sell — is the membership.

Wall Street

CYTK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CYTK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26CYTKHigh $146Median $105Low $83

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says22 analysts
20 Buy2 Hold0 Sell
Low $83Median $105High $146

The green dot is the last close — the median target sits +37.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 July 2026RBC CapitalMaintainsOutperform$119 → $117
29 June 2026UBSUpgradeBuy—
24 June 2026MizuhoMaintainsOutperform—
17 June 2026NeedhamReiteratesBuy—
19 May 2026CitigroupInitiatesBuy—
12 May 2026JP MorganMaintainsOverweight—
11 May 2026HC Wainwright & Co.MaintainsBuy—
7 May 2026Wells FargoMaintainsOverweight—
6 May 2026Morgan StanleyMaintainsOverweight—
6 May 2026RBC CapitalMaintainsOutperform—
6 May 2026StifelMaintainsBuy—
5 May 2026NeedhamMaintainsBuy—
10 Apr 2026Wells FargoInitiatesOverweight—
6 Apr 2026BarclaysMaintainsOverweight—
18 Mar 2026MizuhoMaintainsOutperform—
17 Mar 2026JP MorganMaintainsOverweight—
6 Mar 2026UBSMaintainsNeutral—
26 Feb 2026Leerink PartnersMaintainsOutperform—
25 Feb 2026CitizensMaintainsMarket Outperform—
25 Feb 2026NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

CYTK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
8
Analysts cutting
5
Fundamentals

Cytokinetics, Inc. (CYTK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.7×

Cheaper than 94% of US stocks

Price / sales
98.1×

Cheaper than 4% of US stocks

Price / book
−11.4×

Cheaper than 97% of US stocks

EV / EBITDA
−16.3×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
1125.8%

Higher than 99% of US stocks

Earnings growth (YoY)
1125.8%

Higher than 98% of US stocks

Gross margin
86.8%

Higher than 95% of US stocks

Operating margin
−948.7%

Higher than 6% of US stocks

Net margin
−372.5%

Higher than 1% of US stocks

Returns & dividend
Return on equity
119.0%

Higher than 97% of US stocks

Return on assets
−31.5%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CYTK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CYTKCytokinetics, Inc.$10.4B
74
NUVLNuvalent, Inc.$9.7B
—
HALOHalozyme Therapeutics, Inc.$9.8B
85
KRYSKrystal Biotech, Inc.$10.1B
73
APGEApogee Therapeutics, Inc.$10.1B
45
SMMTSummit Therapeutics, Inc.$10.4B
18
PTGXProtagonist Therapeutics, Inc.$8.7B
86
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CYTK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest CYTK news & analysis

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zacks Investment Research · 30 July 2026positive

Zacks Investment Research reported that Cytokinetics (CYTK) has the right combination of key ingredients for a likely earnings beat in its upcoming Q2 report. The article prepares readers with the key expectations ahead of the release.

Why it matters — An earnings beat could signal strong company performance, making this analysis relevant for CYTK watchers monitoring the stock ahead of the Q2 report.

Cytokinetics wins UK approval, NICE backing for heart disease drug

Reuters · 30 July 2026positive

Britain's medicines regulator approved Cytokinetics' drug for a rare heart condition, and the country's cost-effectiveness watchdog, NICE, recommended it for NHS reimbursement, potentially reaching about 6,600 patients.

Why it matters — CYTK watchers would care because the drug has cleared both regulatory approval and the reimbursement hurdle in the UK, expanding its potential commercial reach.

Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales

GlobeNewsWire · 30 July 2026positive

Cytokinetics announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy in eligible adult patients, alongside positive guidance from NICE.

Why it matters — This regulatory approval and positive reimbursement recommendation in the UK represent a significant commercial milestone for Cytokinetics' key pipeline asset, aficamten.

FAQ

Frequently asked questions about CYTK stock

What is the CYTK stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Cytokinetics, Inc. have a median 12-month price target of $105, with estimates ranging from $83 to $146. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CYTK stock a buy right now?

Of the 22 analysts covering Cytokinetics, Inc., 20 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cytokinetics, Inc. 74 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CYTK?

As at 1 Aug 2026, Cytokinetics, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).

Will CYTK stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +37.3% from the last close, and Ticker Nerd's factor model ranks Cytokinetics, Inc. 74 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CYTK stock forecast for 2030?

No analyst covering Cytokinetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CYTK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $83 to $146 over the next 12 months.

How has CYTK stock performed over the past year?

Cytokinetics, Inc. returned +108.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cytokinetics, Inc. do?

Cytokinetics, Incorporated is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors. These small-molecule therapies target debilitating diseases where muscle performance is compromised or declining, including amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, hypertrophic cardiomyopathy, and chronic obstructive pulmonary disease.

What is the latest news on CYTK?

The most recent item we track (Zacks Investment Research, 30 July 2026): "Cytokinetics (CYTK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release". Zacks Investment Research reported that Cytokinetics (CYTK) has the right combination of key ingredients for a likely earnings beat in its upcoming Q2 report. The article prepares readers with the key expectations ahead of the release.

Company

About Cytokinetics, Inc.

Cytokinetics, Incorporated is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors. These small-molecule therapies target debilitating diseases where muscle performance is compromised or declining, including amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, hypertrophic cardiomyopathy, and chronic obstructive pulmonary disease. By specifically engineering compounds to enhance muscle function and contractility, Cytokinetics addresses impaired muscle function in cardiovascular and neuromuscular conditions. The company advances muscle-directed investigational medicines aimed at improving health outcomes for patients with serious diseases of cardiac and skeletal muscle dysfunction. Founded in 1997 and headquartered in South San Francisco, California, Cytokinetics leverages expertise in muscle biology to build a pipeline of sarcomere-directed therapies, positioning it as a key player in specialized biopharmaceutical innovation for muscle-related disorders.

CEO Mr. Robert I. Blum · 673 employees · United States · https://www.cytokinetics.com